RxDoctor Payments Data

Emily Brooker, PA

Physician Assistant · Phoenix, AZNPI 1114031457

Payments from drug & device makers

$937in general payments, 2019–2025

Across 37 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$188
  • AbbVie$129
  • Avanos Medical$125
  • Collegium Pharmaceutical, Inc.$115
  • Nevro Corp.$90
  • Abbott$73
  • plus $217 from 7 others

What the payments were for

  • Food & beverage$937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$937 in reported general payments places this provider in the 65th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$59,241
Medicare patients
58
Services billed
2,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate19$24,087
BelbucaBuprenorphine Hcl12$13,338
Xtampza ErOxycodone Myristate23$13,236
OxycontinOxycodone Hcl17$11,162
LinzessLinaclotide19$9,609
Fentanyl33$7,280
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen248$6,765
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen269$6,749
MovantikNaloxegol Oxalate11$4,496
Oxycodone Hcl174$3,344
Gabapentin144$2,912
Morphine Sulfate ErMorphine Sulfate83$1,891
Pregabalin74$1,588
Tizanidine Hcl138$1,188
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$115$26,57535 claims
PfizerNurtec Odt$13$24,08719 claims
AbbVieLinzess$129$9,60919 claims
Redhill Biopharma Inc.Movantik$17$4,49611 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl$21$1,89262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →